Arnold & Porter Represents ESTEVE in Finalizing its Acquisition of TerSera IST Unit, Two Specialty Medications

Arnold & Porter recently advised ESTEVE in completing its acquisition of TerSera Therapeutics LLC’s Infusion Specialty Therapies (IST) business unit, including two specialty medications: Prialt^® (ziconotide intrathecal infusion) and Quzyttir^® (cetirizine hydrochloride injection).

With this transaction, ESTEVE has obtained worldwide rights for Quzyttir^® in all territories (except for China) and consolidated its rights for Prialt^® worldwide.

The Arnold & Porter team included partners Tracy Belton, Wayne Janke, and Jeremy Willcocks and senior associates Colleen Couture and Alexus Williams. Partners Kristin Hicks and Liz Lindquist and senior associates Sunha Cha, Phillip DeFedele, and Jonathan Trinh assisted with healthcare regulatory matters. Partners Debbie Feinstein and Bill Efron and counsel Barbara Wootton assisted with U.S. antitrust matters. Partners Zeno Frediani and John Schmidt assisted with international antitrust matters. Counsel Kathleen Wechter and senior associate Kathryn Geoffroy assisted with employee benefits and labor matters. Partner Laurie Abramowitz and associate Sean Kavanaugh assisted with tax matters. Senior counsel Sheryl Gittlitz assisted with finance matters. Counsel Nancy Perkins assisted with CFIUS and data privacy matters. Partner Soo-Mi Rhee and senior associate Junghyun Baek assisted with export control and sanctions matters. Partner Bobby McMillin assisted with legislative and public policy matters. Partner Carmela Romeo and senior associate Sarah Prather assisted with litigation matters. Associates Ally Krenos and Alexis Sabet also assisted in the transaction.